Oricell’s pre-IPO fundraising continued to draw attention as the company moved closer to potential capital-market milestones while scaling its solid-tumor CAR-T platform. Separate deal coverage reiterated the size and structure of the round, and highlighted the centrality of Ori-C101 in hepatocellular carcinoma. The company’s narrative emphasizes that it has already completed early human testing, and expects its next steps to center on pivotal trials. For the cell therapy space, the repeated emphasis on a defined lead asset underlines how sponsors and investors are prioritizing programs with a credible pathway to registrational studies. The financing also connects with broader market appetite for cell therapy companies that can demonstrate both differentiation and execution maturity in solid tumors. This cluster is included to capture the deal’s multiple independent datapoints provided by the source set.